Rediscovery of nefopam for the treatment of neuropathic pain

Korean Journal of Pain

Volumn 27, Issue 2, 2014, Pages 103-111

  Kim, Kyung Hoon ^a   Abdi, Salahadin ^b  

^a Pusan National University School of Medicine   (South Korea)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Adverse drug reactions; Molecular mechanisms of pharmacological action; Nefopam; Neuropathic pain; Nonopioid analgesics

Indexed keywords

ADRENERGIC RECEPTOR; CHLORPROMAZINE; CLONIDINE; DIPHENHYDRAMINE; DOPAMINE; DOPAMINE RECEPTOR; DOPAMINE TRANSPORTER; DULOXETINE; KETAMINE; LIDOCAINE; NARCOTIC ANALGESIC AGENT; NEFOPAM; NONSTEROID ANTIINFLAMMATORY AGENT; NORADRENALIN; NORADRENALIN TRANSPORTER; ORPHENADRINE; PAROXETINE; PETHIDINE; SEROTONIN; SEROTONIN RECEPTOR; SEROTONIN TRANSPORTER; TRAMADOL; VENLAFAXINE; VOLTAGE GATED SODIUM CHANNEL;

ANALGESIC ACTIVITY; ANAPHYLACTIC SHOCK; ANGIONEUROTIC EDEMA; ANTICONVULSANT ACTIVITY; ANTIDEPRESSANT ACTIVITY; AREA UNDER THE CURVE; CALCIUM TRANSPORT; CHRONIC PAIN; COLD SWEAT; CONTINUOUS INFUSION; CONVULSION; DIZZINESS; DROWSINESS; DRUG HALF LIFE; DRUG POTENCY; DRUG STRUCTURE; ERYTHEMA; HALLUCINATION; HICCUP; HUMAN; HYPERALGESIA; LONG TERM POTENTIATION; MALAISE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NEUROMODULATION; NEUROPATHIC PAIN; NEUROTRANSMISSION; NOCICEPTIVE PAIN; NONHUMAN; PAIN ASSESSMENT; PHARMACOLOGICAL BLOCKING; POSTOPERATIVE PAIN; PRURITUS; REVIEW; SHIVERING; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION; TACHYCARDIA; TREATMENT OUTCOME; URTICARIA;

EID: 84897045547     PISSN: 20059159     EISSN: 20930569     Source Type: Journal    
DOI: 10.3344/kjp.2014.27.2.103     Document Type: Review

References (50)

1. Gregori-Puigjané E, Setola V, Hert J, Crews BA, Irwin JJ, Lounkine E, et al. Identifying mechanism-of-action targets for drugs and probes. Proc Natl Acad Sci U S A 2012; 109: 11178-11183.
2. Moore RA, Derry S, McQuay HJ, Wiffen PJ. Single dose oral analgesics for acute postoperative pain in adults. Cochrane Database Syst Rev 2011; (9): CD008659.
3. Alfonsi P, Adam F, Passard A, Guignard B, Sessler DI, Chauvin M. Nefopam, a nonsedative benzoxazocine analgesic, selectively reduces the shivering threshold in unanesthetized subjects. Anesthesiology 2004; 100: 37-43.
4. Heel RC, Brogden RN, Pakes GE, Speight TM, Avery GS. Nefopam: a review of its pharmacological properties and therapeutic efficacy. Drugs 1980; 19: 249-67.
5. Podranski T, Bouillon TW, Riva T, Kurz AM, Oehmke MJ. Compartmental pharmacokinetics of nefopam during mild hypothermia. Br J Anaesth 2012; 108: 784-91.
6. Bassett JR, Cairncross KD, Hacket NB, Story M. Studies on the peripheral pharmacology of fenazoxine, a potential antidepressant drug. Br J Pharmacol 1969; 37: 69-78.
7. Tobin WE, Gold RH. Nefopam hydrochloride: a novel muscle relaxant. J Clin Pharmacol New Drugs 1972; 12: 230-8.
8. Bolt AG, Graham G, Wilson P. Stereoselective demethylation of the enantiomers of nefopam, an experimental antidepressant and skeletal muscle relaxant. Xenobiotica 1974; 4: 355-63.
9. Koe BK. Molecular geometry of inhibitors of the uptake of catecholamines and serotonin in synaptosomal preparations of rat brain. J Pharmacol Exp Ther 1976; 199: 649-61.
10. Cohen A. Nefopam hydrochloride for pain relief. Curr Ther Res Clin Exp 1974; 16: 184-93.
11. Klotz AL. Long-term safety of Nefopam hydrochloride (Acupan), a new analgesic formulation. Curr Ther Res Clin Exp 1974; 16: 602-8.
12. Workmon FC, Winter L Jr. A clinical evaluation of nefopam hydrochloride (Acupan): a new analgesic. Curr Ther Res Clin Exp 1974; 16: 609-16.
13. Kolodny AL, Winter L Jr. Further clinical evaluations of nefopam hydrochloride, a new analgesic. Curr Ther Res Clin Exp 1975; 17: 519-24.
14. Kakkar M, Derry S, Moore RA, McQuay HJ. Single dose oral nefopam for acute postoperative pain in adults. Cochrane Database Syst Rev 2009; (3): CD007442.
15. Izzo V, Mariconti P, Tiengo M. Action and effectiveness of nefopam chloride in the control of postoperative shivering. Minerva Anestesiol 1991; 57: 760-2.
16. Kim YA, Kweon TD, Kim M, Lee HI, Lee YJ, Lee KY. Comparison of meperidine and nefopam for prevention of shivering during spinal anesthesia. Korean J Anesthesiol 2013; 64: 229-33.
17. Park SM, Mangat HS, Berger K, Rosengart AJ. Efficacy spectrum of antishivering medications: meta-analysis of randomized controlled trials. Crit Care Med 2012; 40: 3070-82.
18. Bilotta F, Rosa G. Nefopam for severe hiccups. N Engl J Med 2000; 343: 1973-4.
19. Bilotta F, Pietropaoli P, Rosa G. Nefopam for refractory postoperative hiccups. Anesth Analg 2001; 93: 1358-60.
20. Pajot S, Geeraerts T, Leblanc PE, Duranteau J, Benhamou D. Hiccup during weaning from mechanical ventilation: the use of nefopam. Br J Anaesth 2007; 99: 748-9.
21. Barrot M. Tests and models of nociception and pain in rodents. Neuroscience 2012; 211: 39-50.
22. Jaggi AS, Jain V, Singh N. Animal models of neuropathic pain. Fundam Clin Pharmacol 2011; 25: 1-28.
23. Hunskaar S, Hole K. The formalin test in mice: dissociation between inflammatory and non-inflammatory pain. Pain 1987; 30: 103-14.
24. Cho SY, Park AR, Yoon MH, Lee HG, Kim WM, Choi JI. Antinociceptive effect of intrathecal nefopam and interaction with morphine in formalin-induced pain of rats. Korean J Pain 2013; 26: 14-20.
25. Girard P, Pansart Y, Coppe MC, Gillardin JM. Nefopam reduces thermal hypersensitivity in acute and postoperative pain models in the rat. Pharmacol Res 2001; 44: 541-5.
26. Buritova J, Besson JM. Effects of nefopam on the spinal nociceptive processes: a c-Fos protein study in the rat. Eur J Pharmacol 2002; 441: 67-74.
27. Laboureyras E, Chateauraynaud J, Richebé P, Simonnet G. Long-term pain vulnerability after surgery in rats: prevention by nefopam, an analgesic with antihyperalgesic properties. Anesth Analg 2009; 109: 623-31.
28. Evans MS, Lysakowski C, Tramèr MR. Nefopam for the prevention of postoperative pain: quantitative systematic review. Br J Anaesth 2008; 101: 610-7.
29. Tigerstedt I, Tammisto T, Leander P. Comparison of the analgesic dose-effect relationships of nefopam and oxycodone in postoperative pain. Acta Anaesthesiol Scand 1979; 23: 555-60.
30. Dordoni PL, Della Ventura M, Stefanelli A, Iannace E, Paparella P, Rocca B, et al. Effect of ketorolac, ketoprofen and nefopam on platelet function. Anaesthesia 1994; 49: 1046-9.
31. Gasser JC, Bellville JW. Respiratory effects of nefopam. Clin Pharmacol Ther 1975; 18: 175-9.
32. Guindon J, Walczak JS, Beaulieu P. Recent advances in the pharmacological management of pain. Drugs 2007; 67: 2121-33.
33. Torres GE, Gainetdinov RR, Caron MG. Plasma membrane monoamine transporters: structure, regulation and function. Nat Rev Neurosci 2003; 4: 13-25.
34. Max MB, Gilron IH. Antidepressants, muscle relaxants, and N-methyl-D-aspartate receptor antagonists. In: Bonica's management of pain. 3rd ed. Edited by Loeser JD, Bonica JJ. Philadelphia (PA), Lippincott Williams & Wilkins. 2001, pp 1710-26.
35. Novelli A, Díaz-Trelles R, Groppetti A, Fernández-Sánchez MT. Nefopam inhibits calcium influx, cGMP formation, and NMDA receptor-dependent neurotoxicity following activation of voltage sensitive calcium channels. Amino Acids 2005; 28: 183-91.
36. Verleye M, André N, Heulard I, Gillardin JM. Nefopam blocks voltage-sensitive sodium channels and modulates glutamatergic transmission in rodents. Brain Res 2004; 1013: 249-55.
37. Biella GE, Groppetti A, Novelli A, Fernández-Sánchez MT, Manfredi B, Sotgiu ML. Neuronal sensitization and its behavioral correlates in a rat model of neuropathy are prevented by a cyclic analog of orphenadrine. J Neurotrauma 2003; 20: 593-601.
38. Novelli A, Groppetti A, Rossoni G, Manfredi B, Ferrero- Gutiérrez A, Pérez-Gómez A, et al. Nefopam is more potent than carbamazepine for neuroprotection against veratridine in vitro and has anticonvulsant properties against both electrical and chemical stimulation. Amino Acids 2007; 32: 323-32.
39. Czuczwar M, Czuczwar K, Cieszczyk J, Kis J, Saran T, Luszczki JJ, et al. Nefopam enhances the protective activity of antiepileptics against maximal electroshock-induced convulsions in mice. Pharmacol Rep 2011; 63: 690-6.
40. Löscher W, Schmidt D. New Horizons in the development of antiepileptic drugs: innovative strategies. Epilepsy Res 2006; 69: 183-272.
41. Hoebel BG, Hernandez L, Schwartz DH, Mark GP, Hunter GA. Microdialysis studies of brain norepinephrine, serotonin, and dopamine release during ingestive behavior. Theoretical and clinical implications. Ann N Y Acad Sci 1989; 575: 171-91.
42. Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ, et al. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacol Rev 1994; 46: 157-203.
43. Fink KB, Göthert M. 5-HT receptor regulation of neurotransmitter release. Pharmacol Rev 2007; 59: 360-417.
44. Barnes NM, Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology 1999; 38: 1083-152.
45. Bannister K, Bee LA, Dickenson AH. Preclinical and early clinical investigations related to monoaminergic pain modulation. Neurotherapeutics 2009; 6: 703-12.
46. Cotecchia S, Stanasila L, Diviani D. Protein-protein interactions at the adrenergic receptors. Curr Drug Targets 2012; 13: 15-27.
47. Girault JA, Greengard P. The neurobiology of dopamine signaling. Arch Neurol 2004; 61: 641-4.
48. Benzon HT. The neuropathic pain scales. Reg Anesth Pain Med 2005; 30: 417-21.
49. Mather GG, Labroo R, Le Guern ME, Lepage F, Gillardin JM, Levy RH. Nefopam enantiomers: preclinical pharmacology/ toxicology and pharmacokinetic characteristics in healthy subjects after intravenous administration. Chirality 2000; 12: 153-9.
50. Durrieu G, Olivier P, Bagheri H, Montastruc JL; French Network of Pharmacovigilance Centers. Overview of adverse reactions to nefopam: an analysis of the French Pharmacovigilance database. Fundam Clin Pharmacol 2007; 21: 555-8.